M&T Bank Corp Inhibrx, Inc. Transaction History

M&T Bank Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$32.76 - $39.56 $77,542 - $93,638	-2,367 Reduced 9.93%	21,476 $750,000
Q4 2023 Feb 06, 2024	SELL	$14.5 - $38.0 $67,613 - $177,194	-4,663 Reduced 16.36%	23,843 $906,000
Q3 2023 Nov 02, 2023	BUY	$15.75 - $26.31 $1,606 - $2,683	102 Added 0.36%	28,506 $523,000
Q2 2023 Aug 09, 2023	BUY	$16.96 - $27.82 $111,936 - $183,612	6,600 Added 30.27%	28,404 $737,000
Q1 2023 May 11, 2023	BUY	$18.45 - $27.14 $73,578 - $108,234	3,988 Added 22.38%	21,804 $411,000
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $38,281 - $63,227	1,897 Added 7.01%	28,965 $713,000
Q4 2022 Feb 13, 2023	SELL	$20.18 - $33.33 $224,986 - $371,596	-11,149 Reduced 38.49%	17,816 $438,000
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $70,684 - $150,951	-6,104 Reduced 18.4%	27,068 $486,000
Q2 2022 Aug 05, 2022	BUY	$8.52 - $25.26 $182,575 - $541,296	21,429 Added 182.48%	33,172 $376,000
Q1 2022 May 09, 2022	BUY	$19.89 - $43.18 $19,392 - $42,100	975 Added 9.05%	11,743 $262,000
Q4 2021 Feb 07, 2022	SELL	$26.75 - $46.02 $22,202 - $38,196	-830 Reduced 7.16%	10,768 $470,000
Q3 2020 Nov 06, 2020	BUY	$16.77 - $20.65 $194,498 - $239,498	11,598 New	11,598 $209,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $570M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.